Syndax Pharmaceuticals Inc (SNDX) Receives $15.67 Average PT from Brokerages
Shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) have been assigned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $15.67.
A number of research firms have commented on SNDX. ValuEngine downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a report on Saturday, December 15th. Finally, Nomura lifted their price objective on shares of Syndax Pharmaceuticals to $16.00 and gave the stock a “buy” rating in a report on Friday, March 8th.
A number of institutional investors have recently added to or reduced their stakes in SNDX. Geode Capital Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 180,199 shares of the company’s stock valued at $801,000 after acquiring an additional 6,768 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Syndax Pharmaceuticals by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 810,184 shares of the company’s stock valued at $3,605,000 after acquiring an additional 14,417 shares during the period. Sofinnova Investments Inc. boosted its holdings in shares of Syndax Pharmaceuticals by 102.2% during the fourth quarter. Sofinnova Investments Inc. now owns 350,110 shares of the company’s stock valued at $1,558,000 after acquiring an additional 176,998 shares during the period. 683 Capital Management LLC boosted its holdings in shares of Syndax Pharmaceuticals by 157.7% during the fourth quarter. 683 Capital Management LLC now owns 1,342,839 shares of the company’s stock valued at $5,976,000 after acquiring an additional 821,839 shares during the period. Finally, Paloma Partners Management Co acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at $56,000. 61.88% of the stock is owned by hedge funds and other institutional investors.
Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.02). The business had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 107.73% and a negative net margin of 4,875.48%. On average, research analysts predict that Syndax Pharmaceuticals will post -2.12 EPS for the current year.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Further Reading: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.